Sagimet Biosciences inc (SGMT) - News Archive

: Sagimet Biosciences Inc. recently presented clinical data on its lead compound, denifanstat, at the American Association for the Study of Liver Diseases (AASLD) 2024 meeting. The findings from the subset analysis of t...

Sagimet Biosciences has announced the publication of pivotal results from its Phase 2b FASCINATE-2 clinical trial investigating denifanstat, a novel therapeutic agent targeting biopsy-confirmed F2/F3 Metabolic Dysfuncti...

Analyzing the Future Prospects of Sagimet Biosciences Amid Key DevelopmentsSAN MATEO, Calif. In a strategic move expected to engage both investors and stakeholders alike, Sagimet Biosciences Inc. (NASDAQ: SGMT) has anno...

Sagimet Biosciences Inc (SGMT) is a pharmaceutical company that has been recently influenced by multiple news articles and developments. This article aims to interpret and analyze these articles to assess their impact o...

Sagimet Biosciences Inc., a California-based clinical-stage biopharmaceutical company specializing in the development of novel fatty acid synthase (FASN) inhibitors, announced that it will present verbalized findings fr...

SAN MATEO, Calif., May 06, 2024 - Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company specializing in developing groundbreaking fatty acid synthase (FASN) inhibitors to address d...

Sagimet Biosciences Sets Upcoming IPO to Raise $112.5 MillionSAN MATEO, Calif., Jan. 25, 2024 - Biopharmaceutical company Sagimet Biosciences Inc. (Sagimet) (Nasdaq: SGMT) has recently announced the pricing of its under...

Sagimet Biosciences Announces Proposed Public Offering of Series A Common StockSAN MATEO, Calif., Jan. 23, 2024 - Sagimet Biosciences Inc. (Sagimet) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company revolutioni...

Nonalcoholic steatohepatitis (NASH), a progressive form of nonalcoholic fatty liver disease (NAFLD), has become a major global health concern due to its rising prevalence and lack of approved therapies. However, promisi...

SAN MATEO, Calif., Nov. 28, 2023 - Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company known for its advancements in developing innovative fatty acid synthase (FASN) inhibitors targeting dysfunctional m...